Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus · 2017
Amniotic membrane transplants in the pediatric population.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ahmad Mariam S, Frank Garett S, Hink Eric M, Palestine Alan G, Gregory Darren G, McCourt Emily A
Аннотация
PURPOSE: To investigate the indications for and results of amniotic membrane transplantation (AMT) for the treatment of ocular disease in pediatric patients at a single institution.
METHODS: The medical records of patients <18 years of age who underwent AMT for ocular disease between January 1, 2003, and September 1, 2015, were reviewed retrospectively. Patients were determined to have reached a clinical endpoint if there was resolution of the ocular condition being treated after AMT placement, no additional surgery required for treatment of the ocular condition, and no active disease at most recent follow-up.
RESULTS: A total of 48 records were reviewed. Of these, 32 patients (67%) received AMT for treatment of ocular disease related to Stevens Johnson syndrome (SJS), 29 (94%) of whom reached the clinical endpoint. The remaining 16 patients (33%) underwent AMT for indications other than SJS, including difficult-to-treat corneal epithelial defects and ulcers, conjunctival reconstruction, and scarring after strabismus surgery. Of these, 80% reached the clinical endpoint. There were no adverse effects related to AMT in either group.
CONCLUSIONS: In our series, AMT was used successfully and without complications.
METHODS: The medical records of patients <18 years of age who underwent AMT for ocular disease between January 1, 2003, and September 1, 2015, were reviewed retrospectively. Patients were determined to have reached a clinical endpoint if there was resolution of the ocular condition being treated after AMT placement, no additional surgery required for treatment of the ocular condition, and no active disease at most recent follow-up.
RESULTS: A total of 48 records were reviewed. Of these, 32 patients (67%) received AMT for treatment of ocular disease related to Stevens Johnson syndrome (SJS), 29 (94%) of whom reached the clinical endpoint. The remaining 16 patients (33%) underwent AMT for indications other than SJS, including difficult-to-treat corneal epithelial defects and ulcers, conjunctival reconstruction, and scarring after strabismus surgery. Of these, 80% reached the clinical endpoint. There were no adverse effects related to AMT in either group.
CONCLUSIONS: In our series, AMT was used successfully and without complications.